Production (Stage)
MBX Biosciences, Inc.
MBX
$11.37
-$0.49-4.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -53.21% | 14.09% | -14.41% | -28.53% | -39.51% |
| Total Depreciation and Amortization | 32.76% | -22.67% | 19.05% | 31.25% | 17.07% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 344.92% | -81.33% | 25.15% | -55.90% | 123.63% |
| Change in Net Operating Assets | 195.69% | -122.63% | 37.25% | 365.21% | 115.20% |
| Cash from Operations | -41.41% | -9.36% | -10.50% | -23.90% | 3.91% |
| Capital Expenditure | 67.39% | -61.40% | 87.39% | -65.57% | -396.36% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 104.84% | 33.24% | -1,254.09% | -147.38% | 154.33% |
| Cash from Investing | 104.79% | 33.18% | -1,177.25% | -151.14% | 153.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -97.95% | -99.89% | 348,922.00% | -73.54% | 894.74% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -100.00% | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 85.12% | -21.31% | -30,083.33% | -- |
| Cash from Financing | 103.03% | -100.06% | 13,490.91% | -1,062.30% | 863.16% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 76.71% | -169.39% | 625.09% | -567.61% | 112.23% |